Compounds > agelastatin a
Page last updated: 2024-12-08

agelastatin a

Description

agelastatin A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID177936
CHEMBL ID1096256
SCHEMBL ID4745999
MeSH IDM0438264

Synonyms (17)

Synonym
(-)-agelastatin a
CHEMBL1096256
agelastatin a
agelastatine a
152406-28-5
imidazo(4',5':4,5)cyclopenta(1,2-e)pyrrolo(1,2-a)pyrazine-4,7-dione, 1-bromo-5,5a,5b,6,8,8a,9,9a-octahydro-8a-hydroxy-8-methyl-, (5as-(5aalpha,5bbeta,8abeta,9aalpha))-
SCHEMBL4745999
MPASKXAEPUAMBS-WJOUQXRDSA-N
7MB ,
DTXSID60934493
1-bromo-7,8a-dihydroxy-8-methyl-5a,5b,8,8a,9,9a-hexahydroimidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazin-4(5h)-one
(1r,9s,10s,14s)-3-bromo-14-hydroxy-13-methyl-2,8,11,13-tetrazatetracyclo[7.6.0.02,6.010,14]pentadeca-3,5-diene-7,12-dione
nsc-786147
nsc786147
HY-125132
CS-0089439
AKOS040747602

Research Excerpts

Overview

Agelastatin A is a naturally occurring oroidin alkaloid with powerful antitumor effects that, in many cases, are superior to cisplatin in vitro.

ExcerptReferenceRelevance
"Agelastatin A is a marine alkaloid with potent biological activity. "( The
D'Ambrosio, M, 2023)		2.35
"(-)-Agelastatin A is a naturally occurring oroidin alkaloid with powerful antitumor effects that, in many cases, are superior to cisplatin in vitro."( Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation.
Campbell, FC; Crowe, P; Domostoj, MM; El-Tanani, M; Erwin, PJ; Hale, KJ; Johnston, PG; Manaviazar, S; Mason, CK; McFarlane, S, 2008)		2.27

Treatment

ExcerptReferenceRelevance
"(-)-Agelastatin A treatment also reduced beta-catenin protein expression and reduced anchorage-independent growth, adhesion, and invasion in R37 OPN pBK-CMV and C9 cell lines."( Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation.
Campbell, FC; Crowe, P; Domostoj, MM; El-Tanani, M; Erwin, PJ; Hale, KJ; Johnston, PG; Manaviazar, S; Mason, CK; McFarlane, S, 2008)		2.27

Pharmacokinetics

ExcerptReferenceRelevance
" A detailed in vitro structure-activity relationship of 1a in CLL compared to that of 22 synthetic analogues is described along with preliminary in vivo pharmacokinetic and metabolism studies on the most potent compounds."( Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
Castro, JE; Choi, MY; Molinski, TF; Stout, EP, 2014)		0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1223770Solubility of compound in water at 25 degC2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223775Half life in BALB/c mouse plasma at 2.5 mg/kg, iv administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223795Drug recovery in BALB/c mouse serum at 50 uM after 24 hrs by LC-MS method2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223792Protein binding in BALB/c mouse serum at 50 uM after 1 to 24 hrs by LC-MS method2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223781Cmax in BALB/c mouse plasma at 5 mg/kg, ip administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223774Tmax in BALB/c mouse plasma at 2.5 mg/kg, iv administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223762Antitumor activity against CLL1 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290975Cytotoxicity against human OVACR3 cells after 48 hrs by crystal violet staining based assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223786Metabolic stability in mouse liver microsomes containing glucuronidase2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223796Drug recovery in human AB serum at 50 uM after 24 hrs by LC-MS method2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223782Tmax in BALB/c mouse plasma at 5 mg/kg, ip administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290978Plasma protein binding in human by liquid chromatography-mass spectrometric analysis2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223780AUC in BALB/c mouse plasma at 5 mg/kg, ip administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223765Antitumor activity against human HeLa cells assessed as cell viability by MTT assay2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223768Antitumor activity against CLL5 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223779Half life in BALB/c mouse plasma at 2.5 mg/kg, ip administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID477229Cytotoxicity against human KB cells at 30 uM2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Agelastatin E, agelastatin F, and benzosceptrin C from the marine sponge Agelas dendromorpha.
AID1290973Cytotoxicity against human A3 cells after 48 hrs by crystal violet staining based assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223776AUC in BALB/c mouse plasma at 2.5 mg/kg, ip administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223764Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223777Cmax in BALB/c mouse plasma at 2.5 mg/kg, ip administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290979Metabolic stability in human plasma assessed as drug recovery2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223773Cmax in BALB/c mouse plasma at 2.5 mg/kg, iv administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290982Cytotoxicity against human B cells assessed as cell viability after 24 hrs by annexin V/propidium iodide staining based flow cytometric analysis2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1290969Cytotoxicity against human HeLa cells after 24 hrs by [3H]-thymidine incorporation assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223788Drug excretion in BALB/c mouse urine at 2.5 mg/kg, ip administered as single dose measured after 5 mins by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223794Drug recovery in BALB/c mouse plasma at 50 uM after 24 hrs by LC-MS method2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223784Metabolic stability in human liver microsomes at 100 uM measured after 1 hr by LC/MS analysis in presence of 1 mM NADPH2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223793Protein binding in human AB serum at 50 uM after 1 to 24 hrs by LC-MS method2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223778Tmax in BALB/c mouse plasma at 2.5 mg/kg, ip administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290972Cytotoxicity against human SJSA1 cells after 48 hrs by crystal violet staining based assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223772AUC in BALB/c mouse plasma at 2.5 mg/kg, iv administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223763Antitumor activity against CLL2 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290971Cytotoxicity against human CLL cells after 24 hrs by annexin-V/PI staining based flow cytometry2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223785Metabolic stability in mouse liver microsomes at 100 uM measured after 1 hr by LC/MS analysis in presence of 1 mM NADPH2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290970Cytotoxicity against human IGROV cells after 48 hrs by crystal violet staining based assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223783Half life in BALB/c mouse plasma at 5 mg/kg, ip administered as single dose by LC/MS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290974Cytotoxicity against human A431 cells after 48 hrs by crystal violet staining based assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID477228Cytotoxicity against human KB cells at 3 uM2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Agelastatin E, agelastatin F, and benzosceptrin C from the marine sponge Agelas dendromorpha.
AID1223790Cytotoxicity against human CLL cells2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290976Cytotoxicity against human CLL cells after 24 hrs by annexin-V/PI staining based flow cytometry in presence of human plasma protein2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223766Antitumor activity against CLL3 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290977Cytotoxicity against human CLL cells after 24 hrs by annexin-V/PI staining based flow cytometry in presence of fetal bovine serum2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223769Antitumor activity against CLL6 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223767Antitumor activity against CLL4 cells isolated from CLL patient assessed as cell viability after 48 hrs by FACS analysis2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223789Cytotoxicity against human KB cells2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1290983Cytotoxicity against human T cells assessed as cell viability after 24 hrs by annexin V/propidium iodide staining based flow cytometric analysis2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe.
AID1223771Lipophilicity, log P of compound at 25 degC2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223787Metabolic stability in human liver S9 fraction containing glucuronidase2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
AID1223791Protein binding in BALB/c mouse plasma at 50 uM after 1 to 24 hrs by LC-MS method2014Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12
Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (51.72)29.6817
2010's12 (41.38)24.3611
2020's2 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.73 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetaldehyde
Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.. acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.. aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.. acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats.		7.0710aldehydecarcinogenic agent;
EC 3.5.1.4 (amidase) inhibitor;
electron acceptor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
mutagen;
oxidising agent;
Saccharomyces cerevisiae metabolite;
teratogenic agent
imidazole
imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.		2.0410imidazole
thymine
[no description available]		2.0510pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
sulfamic acid
sulfamic acid: standard in alkalimetry; RN given refers to parent cpd; structure. sulfamic acid : The simplest of the sulfamic acids consisting of a single sulfur atom covalently bound by single bonds to hydroxy and amino groups and by double bonds to two oxygen atoms.		2.0510sulfamic acids
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		2.0410arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		3.1450pyrrole;
secondary amine
aziridine
[no description available]		2.0610azacycloalkane;
aziridines;
saturated organic heteromonocyclic parent		alkylating agent
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		2.7230cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
kainic acid
Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.		2.110dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
palladium
Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.		7.4420metal allergen;
nickel group element atom;
platinum group metal atom
1,4-thioxane
1,4-thioxane: structure in first source		2.0510
7-ethoxycoumarin
7-ethoxycoumarin : A member of the class of coumarins that is umbelliferone in which the hydroxy group at position 7 is replaced by an ethoxy group.		2.110aromatic ether;
coumarins
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		4.73280carbamate ester;
oxazolidinone		metabolite
mci 9038
[no description available]		2.0410peptide
arabitol
arabitol: RN given refers to cpd without isomeric designation. arabinitol : A pentitol that is the sugar alcohol produced by the reduction of arabinose or lyxose. It is found in serum or urine of human infected with Candida albicans.. D-arabinitol : The D-enantiomer of arabinitol.		2.0310arabinitol
cyanates
Cyanates: Organic salts of cyanic acid containing the -OCN radical.. cyanates : Salts and esters of cyanic acid, HOC#N; compounds carrying the cyanate functional group -O-C#N.. isocyanates : Organonitrogen compounds that are derivatives of isocyanic acid; compounds containing the isocyanate functional group -N=C=O (as opposed to the cyanate group, -O-C#N).		2.0310
proline
Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.		2.0710amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
sceptrin
sceptrin: structure given in first source; isolated from marine sponges of the genus Agelas; RN from CHEMLINE		2.0510pyrroles;
secondary carboxamide
manzacidin a
manzacidin A: structure in first source		2.0510
fludarabine
[no description available]		2.110purine nucleoside
selenium
Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.		2.0410chalcogen;
nonmetal atom		micronutrient
hymenidin
hymenidin: serotonergic receptor antagonist from Okinawan marine sponge Hymeniacidon; structure given in first source		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
B-Cell Chronic Lymphocytic Leukemia
[description not available]		02.110
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		02.110
Experimental Neoplasms
[description not available]		02.1510
Hematologic Malignancies
[description not available]		02.1510
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		02.1510
Metastase
[description not available]		02.0410
Invasiveness, Neoplasm
[description not available]		02.0410
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.0410
Benign Neoplasms
[description not available]		02.0410
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0410
chemdatabank.com